GSK Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BN7SWP63
GBP
18.26
0.07 (0.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About GSK Plc stock-summary
stock-summary
GSK Plc
Pharmaceuticals & Biotechnology
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Company Coordinates stock-summary
Company Details
G S K House, 980 Great West Road , BRENTFORD None : TW8 9GS
stock-summary
Tel: 44 20 80475000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 10 Foreign Institutions (0.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Sir. Jonathan Symonds
Independent Non-Executive Chairman of the Board
Ms. Emma Walmsley
Chief Executive Officer, Executive Director
Mr. Iain Mackay
Chief Financial Officer, Executive Director
Mr. Charles Bancroft
Non-Executive Director
Mr. Marvinder Banga
Senior Non-Executive Independent Director
Dr. Vivienne Cox
Independent Non-Executive Director
Ms. Lynn Elsenhans
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7,986 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,646 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 74,438 Million ()

stock-summary
P/E

13.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

265.76%

stock-summary
Debt Equity

1.08

stock-summary
Return on Equity

43.25%

stock-summary
Price to Book

4.61